Revolution Medicines’ daraxonrasib, a pan-RAS inhibitor, delivered a clinically meaningful overall survival benefit in a Phase 3 trial in advanced pancreatic ductal adenocarcinoma, according to results presented at ASCO 2026 and published in The New England Journal of Medicine. In the RASolute 302 study of 500 previously treated patients, median survival rose to 13.2 months with daraxonrasib versus 6.7 months with standard-of-care chemotherapy. The study also showed a longer time before disease worsening, with patients on daraxonrasib not seeing progression for 7.2 months compared with 3.6 months for chemotherapy. The results were largely consistent in the subset with the most common RAS mutation profile, reinforcing the therapy’s broad pathway engagement in a disease where targeted options have historically been limited.